Press Releases
Events

 

 

DOBI MEDICAL INTERNATIONAL TO PRESENT AT SMi ANGIOGENESIS CONFERENCE IN LONDON

Return to Press Releases

Mahwah, NJ, May 14, 2004 - Phillip C. Thomas, Chief Executive Officer of DOBI Medical International, Inc. (OTCBB: DBMI) and Angelo Secci, MD, Vice President, Clinical Research, will present an overview of their new optical breast imaging technology at the SMi Angiogenesis Conference at the Hatton Conference Center in London, England. Mr. Thomas and Dr. Secci will be presenting at 11:20 a.m. local time on May 17.

Mr. Thomas will introduce DOBI Medical International, a medical imaging company developing a new methodology for the improved diagnosis of cancer through the identification of angiogenesis – the excess vascularization often associated with tumors. He will also give an overview of the Company’s ComfortScan™ system, which is designed as a non-invasive, optical breast imaging device, to assist in the detection of breast cancer.

Dr. Secci, a clinical scientist and physician with an in-depth background in medical imaging and clinical research will review the external pressure stimulus hypothesis which shows the differential rate of re-engorgement of blood in normal breast tissue compared with that in which angiogenesis is present. In addition, he will discuss the physiological basis for the interpretation of ComfortScan images, as well as the optical operating components of the system and several case studies depicting the utility of the ComfortScan system’s images in detecting whether or not suspicious breast lesions were malignant.

DOBI Medical has completed 4 of 5 modules of its premarket application process for final FDA acceptance of its ComfortScan™ system. The Company currently expects to submit its fifth and final PMA module to the FDA in the second half of 2005. The ComfortScan system is currently investigational and not yet for sale in the United States. International sales of the ComfortScan system are expected to commence in Q4 of this year. Earlier this month, DOBI Medical announced that it had received renewal of its CE Mark Certification that will allow the shipment of its ComfortScan system to European Union Countries and other countries where the CE Mark certification is recognized.

About DOBI Medical International, Inc.
DOBI Medical is a development stage medical imaging company working to create a new means for the improved diagnosis of cancer through the detection of abnormal vascularization ("angiogenesis") associated with tumors. DOBI Medical’s first application of the technology is the ComfortScan system, a non-invasive, non-ionizing, and pain-free dynamic optical imaging system designed to assist physicians in the detection and management of breast cancer. The ComfortScan system is intended to achieve this by providing new, physiology-based imagery of abnormal vascularization in the breast that are not readily available today.

CAUTIONARY STATEMENT PURSUANT TO SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements contained in this press release may contain information that includes or is based upon certain “forward-looking statements” within the meaning of the Securities Litigation Reform Act 1995 relating to the business of DOBI Medical. These forward-looking statements represent management’s current judgment and assumptions and can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements are frequently accompanied by the use of such words as “anticipate”, “plans”, “believes”, “expects”, “project”, “intends”, or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties, including uncertainties relating to our ability to secure additional financing; success of product development efforts; our ability to timely meet federal, local and foreign government and industry regulations and standards; timely and successful completion of our patient clinical trials and submission of our premarket approval application to the FDA; final approval of our ComfortScan system by the FDA; delays in the manufacturing process caused by our inabilities or the inabilities of our subcontractors to timely meet our specifications; our ability to establish international and domestic distribution networks, our ability to timely export our products to international markets; acceptance and use of our ComfortScan system by physicians, imaging clinics, and patients; our ability to obtain third party payer reimbursement; and our ability to compete on price and quality. Any one of these or other risks and uncertainties may cause actual results to be materially different from those described herein or elsewhere by us. Certain of these risks and uncertainties are or will be described in greater detail in our filings from time to time with the Securities and Exchange Commission, which we strongly urge you to read, including our 2003 Annual Report on Form 10-KSB filed on February 18, 2004. Subsequent written and oral forward looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements and risk factors set forth above and elsewhere in our reports filed with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward looking statements.

Return to Press Releases

For further information:
Please contact: Phillip C. Thomas, Chief Executive Officer
201-760-6464
pct@igaot.pt

DOBI Medical International
1200 MacArthur Blvd.
Mahwah, New Jersey 07430
Voice: (201) 760 6464
Fax: (201) 760 8860
e-mail: information@igaot.pt

 
 


calendario | newsletter | relacoes | atribuicoes | acidentesincidentes | legisot | reflegisd | apresentacao | missao | contactos
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 1 | 2 | 3 | 4 | 5